Enhancing siRNA delivery by employing lipid nanoparticles

Therapeutic Delivery

Volumn 5, Issue 6, 2014, Pages 663-673

  Hope, Michael J ^a  

^a 204 2389 Health Sciences Mall   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LIPID NANOPARTICLE; LIPOSOME; MACROGOL; NANOCARRIER; PLASMID DNA; PREALBUMIN; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS MESSENGER RNA;

AMYLOIDOSIS; ANTIVIRAL THERAPY; CYTOPLASM; GENE SILENCING; HUMAN; HYPERCHOLESTEROLEMIA; LIPOSOMAL DELIVERY; LIVER CELL; MALIGNANT NEOPLASTIC DISEASE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TARGET CELL; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; LIPIDS; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84905506792     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.37     Document Type: Review

References (70)

1. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
2. Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 71(3), 555-564 (2013).
3. Hagemeister F, Rodriguez MA, Deitcher SR et al. Long term results of a Phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br. J. Haematol. 162(5), 631-638 (2013).
4. Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of vincristine sulfate liposome injection (Marqibo®) and rituximab for patients with relapsed and refractory diffuse large B-cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin. Lymphoma Myeloma. Leuk. 14(1), 37-42 (2013).
5. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta 1152(2), 253-258 (1993).
6. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 50, 575-579 (1990).
7. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72, 896-904 (1995).
8. Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert. Opin. Drug Deliv. 7(12), 1329-1341 (2010).
9. Wilschut J. Influenza vaccines: the virosome concept. Immunol. Lett. 122(2), 118-121 (2009).
10. Cullis PR, Fenske DB, Hope MJ. Physical propereties and functional roles of lipids in membranes. In: Biochemistry of Lipids, Lipoproteins and Membranes. Vance DE, Vance JE (Eds). Elsevier Sciences, Oxford, UK, 1-33 (1996).
11. Felgner PL, Gadek TR, Holm M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84(21), 7413-7417 (1987).
12. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 337, 387-388 (1989).
13. Hope MJ, Mui B, Ansell S, Ahkong QF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (Review). Mol. Membr. Biol. 15, 1-14 (1998).
14. Mui B, Ahkong QF, Chow L, Hope MJ. Membrane perturbation and the mechanism of lipid-mediated transfer of DNA into cells. Biochim. Biophys. Acta 1467(2), 281-292 (2000).
15. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15, 647-652 (1997).
16. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068(2), 133-141 (1991).
17. Torchilin VP, Papisov MI. Why do polyethylene glycolcoated liposomes circulate so long? J. Liposome Res. 4, 725-739 (1994).
18. Maurer N, Wong KF, Stark H et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. 80(5), 2310-2326 (2001).
19. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J. Pharmacol. Exp. Ther. 312(3), 1020-1026 (2005).
20. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18(7), 1357-1364 (2010).
21. Mui BL, Tam YK, Jayaraman M et al. Influence of PEG-lipid exchange rate on LNP pharmacokinetics and pharmacodynamics. Mol. Ther. Nucleic Acids (In Press) (2013).
22. Song LY, Ahkong QF, Rong Q et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim. Biophys. Acta 1558(1), 1-13 (2002).
23. Behr JP. Gene transfers with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjug. Chem. 5, 382-389 (1994).
24. Bennett CF, Mirejovsky D, Crooke RM et al. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J. Drug Target. 5(3), 149-162 (1998).
25. Felgner JH, Kumar R, Sridhar CN et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269(4), 2550-2561 (1994).
26. Bailey AL, Cullis PR. Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry 33(42), 12573-12580 (1994).
27. Bailey AL, Cullis PR. Membrane fusion with cationic liposomes: effects of target membrane lipid composition. Biochemistry 36, 1628-1634 (1997).
28. Semple SC, Klimuk SK, Harasym TO et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 1510(1-2), 152-166 (2001).
29. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin. Cancer Res. 11(5), 1990-1998 (2005).
30. Leonetti C, Biroccio A, Benassi B et al. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther. 8(6), 459-468 (2001).
31. Leonetti C, Biroccio A, DAngelo C, Semple SC, Scarsella M, Zupi G. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormonerefractory prostate cancer. Prostate 67(13), 1475-1485 (2007).
32. Klimuk SK, Semple SC, Nahirney PN et al. Enhanced antiinflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. J. Pharmacol. Exp. Ther. 292(2), 480-488 (2000).
33. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
34. Bramson JL, Bodner CA, Johnson J, Semple S, Hope MJ. Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells. Antisense Nucleic Acid Drug Dev. 10(3), 217-224 (2000).
35. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163(3), 1552-1561 (1999).
36. Mui B, Raney SG, Semple SC, Hope MJ. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 298(3), 1185-1192 (2001).
37. Robbins M, Judge A, Ambegia E et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. (2008).
38. De Jong S, Chikh G, Sekirov L et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother. 56(8), 1251-1264 (2007).
39. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19(2), 111-124 (2008).
40. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006).
41. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107(2), 276-287 (2005).
42. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8(15), 1188-1196 (2001).
43. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010).
44. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J. Clin. Invest. 117(1), 94-98 (2007).
45. Jonas A, Phillips MC. Lipoprotein structure. In: Biochemistry of Lipids, lipoproteins and Membranes. Vance DE, Vance JE (Eds). Elsevier, Oxford, UK, 485-506 (2008).
46. Leung AK, Hafez IM, Baoukina S et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J. Phys. Chem. C. Nanomater. Interfaces 116(34), 18440-18450 (2012).
47. Crawford R, Dogdas B, Keough E et al. Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. Int. J. Pharm. 403(1-2), 237-244 (2011).
48. Zhang L, Song J, Cavigiolio G et al. Morphology and structure of lipoproteins revealed by an optimized negativestaining protocol of electron microscopy. J. Lipid Res. 52(1), 175-184 (2011).
49. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 267(26), 18759-18765 (1992).
50. Semple SC, Chonn A, Cullis PR. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev. 32(1-2), 3-17 (1998).
51. Akinc A, Zumbuehl A, Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26(5), 561-569 (2008).
52. Jayaraman M, Ansell SM, Mui BL et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed Engl. 51(34), 8529-8533 (2012).
53. Lin PJ, Tam YY, Hafez I et al. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine 9(2), 233-246 (2013).
54. Yan X, Kuipers F, Havekes LM et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem. Biophys. Res. Commun. 328(1), 57-62 (2005).
55. Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc. Natl Acad. Sci. USA 108(36), 14813-14818 (2011).
56. Nguyen D, Dhanasekaran P, Phillips MC, Lund-Katz S. Molecular mechanism of apolipoprotein E binding to lipoprotein particles. Biochemistry 48(13), 3025-3032 (2009).
57. Coelho T, Adams D, Silva A et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369(9), 819-829 (2013).
58. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase 1 trial. Lancet 383(9911), 60-68 (2013).
59. Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105(33), 11915-11920 (2008).
60. Love KT, Mahon KP, Levins CG et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107(5), 1864-1869 (2010).
61. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23(8), 1002-1007 (2005).
62. Geisbert TW, Lee AC, Robbins M et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729), 1896-1905 (2010).
63. Ursic-Bedoya R, Mire CE, Robbins M et al. Protection against lethal marburg virus infection mediated by lipid encapsulated small interfering RNA. J. Infect. Dis. (2013).
64. Gilleron J, Querbes W, Zeigerer A et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31(7), 638-646 (2013).
65. Pei Y, Hancock PJ, Zhang H et al. Quantitative evaluation of siRNA delivery in vivo. RNA. 16(12), 2553-2563 (2010).
66. Wooddell CI, Rozema DB, Hossbach M et al. Hepatocytetargeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21(5), 973-985 (2013).
67. Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. J. Hepatol. 59(6), 1354-1359 (2013).
68. Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. (2011).
69. Kariko K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther. 20(5), 948-953 (2012).
70. Phua KK, Leong KW, Nair SK. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J. Control. Release 166(3), 227-233 (2013).